We also predicted the prognostic value and efficacy of RFC4 in the immunotherapy cohort using the Kaplan–Meier Plotter website, and we found that the AUC values of RFC4 exceeded 0.5 in all of the anti‐PD‐1 treatment cohorts, with high expression of RFC4 being a protective factor in the Bladder and Melanoma samples, and the high RFC4 expression was a risk factor in Glioblastoma samples, but there was difference in RFC4 expression between the drug‐responsive and non‐responsive groups in the three tumour samples (Figure S13A–C). The gene discussed is RFC4; the disease is melanoma.